Clinical Trials Browser

Phase 3 × Gastrointestinal Neoplasms × durvalumab × Clear all

NCT04592913 2025-12-24

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Phase 3 Active not recruiting

957 enrolled 3 FDA

Gastrointestinal

Gastrointestinal Neoplasms